- The new type of immunotherapy may eliminate all advanced tumor cells
- What are the symptoms of lung cancer bone metastasis?
- All types of coffee can reduce the risk of chronic liver disease
- World’s first mRNA vaccine against influenza begins human clinical trials
- Why do silicone implants cause cancer or fibrous capsule contracture?
- Screening and Prevention of Colorectal Cancer and Breast Cancer
After being injected with a personalized anti-cancer vaccine, survived without recurrence after 5 years of follow-up!
Patients with glioblastoma (GBM) survived 5 years after receving cancer vaccine. In recent years, the incidence of glioma has increased at an annual rate of 1% to 2%.
As the most common malignant brain tumor, glioma has a high degree of malignancy, rapid growth, short course of disease, easy recurrence after surgery, and high disability. It is considered to be one of the most difficult and refractory tumors in neurosurgical treatment. In recent years, the incidence of glioma has increased at an annual rate of 1% to 2%, and it is more common in teenagers and people over 40.
Among them, glioblastoma (GBM) is the most malignant brain glioma, accounting for half of all gliomas and 15% of all primary brain tumors.
Even if the surgical resection is clean, the average time to tumor recurrence is only 6.9 months, the median survival time is only 14.6 months, and the 5-year survival rate is only 4.7%, which is still less than 1/3 of the 5-year survival rate of lung cancer. The prognosis Very bad.
At present, the standard treatment plan for glioblastoma is based on surgical resection, supplemented by comprehensive treatments such as radiotherapy and drug chemotherapy, but unfortunately, the recurrence rate of glioblastoma is as high as 100%. Once it recurs , The treatment options are very limited, and the treatment effect is not ideal, so medical researchers strive to find new treatment methods.
In recent years, the development of tumor immunotherapy has continued to mature. Among them, dendritic cell vaccines have a place in immunotherapy, and can be used as a promising immunotherapy method for various tumors. It is used in glioblastoma and other high-grade gliomas. The treatment has also received more and more attention.
Since 2010, the U.S. Food and Drug Administration (FDA) approved the first dendritic cell vaccine Provenge (sipuleucel-T) for the treatment of refractory prostate cancer; Breast cancer, bladder cancer, kidney cancer, colon cancer, rectal cancer, lung cancer, and melanoma have all achieved good results. The above-mentioned preliminary results obtained in the clinic are currently the basis for clinical trials of high-grade glioma dendritic cell vaccines.
After injection of dendritic cell vaccine, patients with malignant brain tumors are still alive without recurrence after 5 years of follow-up!
A related study on the feasibility, safety, and induction of systemic and intracranial T cell responses of dendritic cell vaccines in patients with glioblastoma multiforme was published in the internationally renowned journal Clinical Cancer Research.
Among the 12 patients, the overall survival of two long-term (≥4 years) glioblastoma multiforme survivors was 100% at 6 months, 75% at 1 year, and 50% at 2 years; The median overall survival time was 23.4 months.
In one patient, 2 months after the completion of peptide-pulse dendritic cell vaccination and any other adjuvant therapy, magnetic resonance imaging (MRI) showed that the residual tumor had almost completely resolved. Interestingly, after nearly 5 years of follow-up, she is currently alive and there is no clinical or MRI evidence of tumor recurrence.
MRI scan of patient 5’s brain
A: Before dendritic cell injection
B: 2 months after completing the peptide-pulsed dendritic cell vaccine series
(The area indicated by the arrow disappeared after the dendritic cell vaccine treatment)
In fact, dendritic cell vaccines have already made many major breakthroughs in animal experiments and early clinical trials. Among them, the development of dendritic cell vaccines for brain tumor, kidney cancer, and melanoma has entered the phase III clinical trial stage and is expected to be marketed.
The dawn of a new type of dendritic cell vaccine has appeared, with an overall survival time of 76% at 15 months!
On April 8, 2020, the Phase II clinical trial data of the new dendritic cell therapy AV-GBM-1 was announced. The study showed that this new vaccine is extremely effective in prolonging the mid-term overall survival of newly diagnosed glioblastoma patients. Great potential.
The 15-month overall survival rate of the 50 evaluable patients who received AV-GBM-1 treatment was 76%, while the 12-month and 15-month overall survival rates of the 287 patients in the control group who received standard treatment, respectively They are 61% and 48%. This shows that the 15-month overall survival rate of patients receiving AV-GBM-1 treatment has increased by 28%, and the effect is particularly significant.
AV-GBM-1 is a patient’s own specific dendritic cell vaccine, which aims to use the patient’s own immune system to find and eliminate cancer cells. This dendritic cell vaccine can carry specific antigens extracted from tumor tissues after surgery. After the injection, the antigen information is transmitted to the T cells to stimulate the tumor-killing activity. Although the autologous vaccine for patients is logically complicated, it is a feasible method that can be administered simultaneously with temozolomide and radiotherapy; it can also be injected with AV-GBM-1 vaccine after recovery from chemotherapy and radiotherapy. If patients can successfully perform single-disciplinary white blood cell collection, they are eligible to participate in the study under the age of 70.
This therapy is theoretically applicable to all solid tumors, so in addition to glioblastoma, Aivita Biomedical is also conducting clinical trials of two other AV-GBM-1 in other tumor types.
Expected to be approved for marketing-a new diagnosis of glioma DCVax-L vaccine
On May 29, 2018, Northwest Biology disclosed the phase III interim data of its personalized autologous dendritic cell vaccine DCVax-L: a personalized glioblastoma vaccine may prolong the long-term survival of some patients. The vaccine, called DCVax-L, uses the patient’s own dendritic cells to help activate the immune system to fight cancer.
Nearly 30% of the patients in the trial have survived for at least three years since they were enrolled in the clinic (the patients will continue to be followed up).
It is worth mentioning that this study is the largest clinical trial of a customized vaccine in patients with fatal brain cancer diagnosed so far.
Between July 2007 and November 2015, the vaccine was administered to newly diagnosed glioblastoma patients in 80 locations around the world, and all patients received standard treatment (surgical removal of the tumor, followed by surgery) before participating in the trial. Chemotherapy).
Due to the crossover design of the trial, nearly 90% of the patients received the vaccine treatment in the end.
The interim trial data of the previously announced phase III clinical study. Among the patients enrolled in the clinic for more than three years, 67 cases (30%) survived more than 30 months, and 44 cases (24.2%) survived more than 36 months. The median survival time of these patients is estimated to be 46.5 to 88.2 months. At the time of analysis, 108 (32.6%) of the 331 patients who participated in the trial were still alive.
So far, the clinical trials of DCVax-L have been conducted for 12 years, which is extraordinary. The first patient was enrolled 12 years ago, and the last patient was enrolled 5 years ago. Everyone is looking forward to the final data of this therapy, and also looking forward to its approval as the first immunotherapy for brain tumors as soon as possible!
Patients with glioblastoma (GBM) survived 5 years after receving cancer vaccine
(source:internet, reference only)